Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury
HRS-AKI treatment and outcomes differ between the United Kingdom and the United States, attributed to the historical standard of care MO in the United States. In adjusted analyses, real-world use of terlipressin was more effective than MO at improving kidney function and achieving HRS-AKI reversal.
Authors
- Xingyue Huang (ORCID: https://orcid.org/0000-0001-9761-505X)
- Stevan A. Gonzalez
- Douglas A. Simonetto (ORCID: https://orcid.org/0000-0003-4095-8144)
- Viktor Chirikov (ORCID: https://orcid.org/0000-0002-9480-0580)
- Kevin Moore
- Andrew S. Allegretti
- Wei-Jhih Wang
Institutions
- Open Society Foundations (US)
- Mayo Clinic (US)
- The Royal Free Hospital (GB)
- Massachusetts General Hospital (US)
- Mallinckrodt (United States) (US)
- Baylor Scott & White All Saints Medical Center (US)
- University College London (GB)
Publication Details
- Journal
- Clinical and Translational Gastroenterology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.14309/ctg.0000000000000951
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00